Camlin Fine Sciences (532834) Aktienübersicht
Camlin Fine Sciences Limited ist zusammen mit seinen Tochtergesellschaften in der Forschung, Entwicklung, Herstellung und Vermarktung von Spezialchemikalien, Inhaltsstoffen und Zusatzstoffmischungen in Indien und international tätig. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 4/6 |
| Künftiges Wachstum | 4/6 |
| Vergangene Leistung | 0/6 |
| Finanzielle Gesundheit | 3/6 |
| Dividenden | 0/6 |
532834 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Camlin Fine Sciences Limited Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | ₹124.75 |
| 52-Wochen-Hoch | ₹298.00 |
| 52-Wochen-Tief | ₹96.30 |
| Beta | 0.64 |
| 1 Monat Veränderung | -9.76% |
| 3 Monate Veränderung | 17.27% |
| 1 Jahr Veränderung | -57.21% |
| 3 Jahre Veränderung | -20.49% |
| 5 Jahre Veränderung | -37.28% |
| Veränderung seit IPO | 1,367.65% |
Aktuelle Nachrichten und Updates
Narrative-Update • Jul 07
532834: Future Profit Margins And New Global CFO Role Will Drive Upside
Analysts have trimmed their price target for Camlin Fine Sciences from ₹190.00 to ₹165.00, reflecting updated assumptions that combine a lower revenue growth outlook with higher expected profit margins and a reduced future P/E multiple. What's in the News for Camlin Fine Sciences Camlin Fine Sciences plans to re-designate current CFO Mr. Santosh Parab as President, Strategy and Global CFO, effective August 18, 2026, following approval at the AGM scheduled for August 11, 2026.
Narrative-Update • Jun 23
532834: Capital Structure Changes Will Support Bullish Outlook Despite CFO Role Shift
Analysts have kept their fair value estimate for Camlin Fine Sciences steady at ₹177.5, with only marginal tweaks to inputs such as the discount rate, revenue growth, profit margin and future P/E assumptions guiding the unchanged price target. What's in the News Camlin Fine Sciences has scheduled a Board meeting on May 26, 2026 to consider and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, and to approve the 33rd AGM to be held on August 11, 2026, along with other business matters, according to a Board meeting notice.Narrative-Update • Jun 06
532834: Upcoming Capital Decisions Will Support Bullish Outlook Despite Leadership Restructuring
Analysts have trimmed the price target on Camlin Fine Sciences from ₹182.5 to ₹177.5, citing updated assumptions on discount rate, revenue growth, profit margin and future P/E that collectively point to a slightly lower fair value estimate. What's in the News Board meeting scheduled for May 26, 2026, to review and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, and to finalize details for the 33rd AGM on August 11, 2026.Narrative-Update • May 22
532834: Upcoming Capital Decisions Will Support Bullish Outlook With Stable Assumptions
Analysts have kept the price target for Camlin Fine Sciences steady at ₹182.5, with the slight tweaks in discount rate and forward P/E mainly fine tuning their valuation framework rather than signaling a major shift in outlook. What's in the News Board meeting scheduled on May 26, 2026 to consider and approve the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026 (Key Developments).Recent updates
Narrative-Update • Jul 07
532834: Future Profit Margins And New Global CFO Role Will Drive Upside
Analysts have trimmed their price target for Camlin Fine Sciences from ₹190.00 to ₹165.00, reflecting updated assumptions that combine a lower revenue growth outlook with higher expected profit margins and a reduced future P/E multiple. What's in the News for Camlin Fine Sciences Camlin Fine Sciences plans to re-designate current CFO Mr. Santosh Parab as President, Strategy and Global CFO, effective August 18, 2026, following approval at the AGM scheduled for August 11, 2026.Narrative-Update • Jun 23
532834: Capital Structure Changes Will Support Bullish Outlook Despite CFO Role Shift
Analysts have kept their fair value estimate for Camlin Fine Sciences steady at ₹177.5, with only marginal tweaks to inputs such as the discount rate, revenue growth, profit margin and future P/E assumptions guiding the unchanged price target. What's in the News Camlin Fine Sciences has scheduled a Board meeting on May 26, 2026 to consider and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, and to approve the 33rd AGM to be held on August 11, 2026, along with other business matters, according to a Board meeting notice.Narrative-Update • Jun 06
532834: Upcoming Capital Decisions Will Support Bullish Outlook Despite Leadership Restructuring
Analysts have trimmed the price target on Camlin Fine Sciences from ₹182.5 to ₹177.5, citing updated assumptions on discount rate, revenue growth, profit margin and future P/E that collectively point to a slightly lower fair value estimate. What's in the News Board meeting scheduled for May 26, 2026, to review and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, and to finalize details for the 33rd AGM on August 11, 2026.Narrative-Update • May 22
532834: Upcoming Capital Decisions Will Support Bullish Outlook With Stable Assumptions
Analysts have kept the price target for Camlin Fine Sciences steady at ₹182.5, with the slight tweaks in discount rate and forward P/E mainly fine tuning their valuation framework rather than signaling a major shift in outlook. What's in the News Board meeting scheduled on May 26, 2026 to consider and approve the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026 (Key Developments).Narrative-Update • Apr 26
532834: Upcoming Meetings Will Support Bullish Outlook With Stable Forward Assumptions
Analysts have left the Camlin Fine Sciences price target unchanged at ₹182.5, explaining that a slightly lower discount rate and marginally higher profit margin assumptions are balanced by a modestly lower future P/E input. What's in the News Special and Extraordinary Shareholders Meeting scheduled via postal ballot in India on May 7, 2026, indicating upcoming shareholder decisions that may affect the company structure or capital plans (Key Developments).Narrative-Update • Apr 11
532834: Upcoming Meetings Will Support Confident Outlook Despite Revised Forecast Assumptions
Analysts have trimmed their price target on Camlin Fine Sciences from ₹235 to ₹182.5. This reflects updated assumptions around fair value, revenue growth, profit margins and future P/E expectations. What's in the News Board meeting scheduled for Feb 13, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended Dec 31, 2025 (Key Developments).Narrative-Update • Mar 25
532834: Upcoming Results Meeting Will Reinforce Steady Assumptions Supporting Upside Potential
Analysts have kept the fair value estimate for Camlin Fine Sciences steady at ₹235, with only minor tweaks to assumptions on discount rate, revenue growth, profit margin and future P/E, resulting in a largely unchanged price target narrative. What's in the News Board meeting scheduled on February 13, 2026 to consider and approve the unaudited standalone financial results for the quarter and nine months ended December 31, 2025 (company filing).Narrative-Update • Mar 10
532834: Scheduled Results Review Will Confirm Steady Assumptions Supporting Upside Potential
Analysts have kept their fair value estimate for Camlin Fine Sciences steady at ₹235, citing largely unchanged assumptions around revenue growth, profit margins and future P/E, with only minor tweaks to the discount rate and valuation inputs. What's in the News Board meeting scheduled for February 13, 2026, to review and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (company filing).Narrative-Update • Feb 24
532834: Upcoming Results Review Will Support Long Term Upside Potential
Analysts have adjusted their fair value estimate for Camlin Fine Sciences from ₹240 to ₹235, reflecting updated views on the discount rate, revenue growth, profit margin and future P/E assumptions. What's in the News A board meeting is scheduled for February 13, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (company filing).Narrative-Update • Feb 09
532834: Upcoming Board And Director Decisions Will Support Long Term Upside
Analysts have maintained their fair value estimate for Camlin Fine Sciences at ₹240.00, with the small adjustments in discount rate and future P/E assumptions reflecting updated views on risk and valuation drivers rather than a change in the headline price target. What's in the News Board meeting scheduled for February 13, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (Key Developments).Narrative-Update • Jan 25
532834: Director Reappointment And Steady Assumptions Will Support Long Term Upside
Analysts have kept their fair value estimate for Camlin Fine Sciences steady at ₹240.0 per share, with the unchanged target reflecting consistent assumptions on revenue growth, profit margin and future P/E, alongside a slightly updated discount rate input. What's in the News A board meeting is scheduled for Nov 10, 2025, to consider and approve the unaudited standalone and consolidated financial results for the quarter and half year ended Sep 30, 2025, and to discuss other matters (Key Developments).Narrative-Update • Jan 11
532834: Governance Continuity And Stable Assumptions Will Support Long Term Upside
Analysts have kept their price target for Camlin Fine Sciences steady at ₹240.00. This reflects updated assumptions around a slightly higher discount rate and fine-tuned estimates for revenue growth, profit margin and future P/E, without a clear tilt in either a more optimistic or more cautious direction.Narrative-Update • Dec 24
532834: Share Swap And Governance Stability Will Drive Long Term Returns
Analysts have maintained their price target for Camlin Fine Sciences at ₹240.00, with only marginal tweaks to the underlying model inputs. This reflects steady confidence in the company’s growth and profitability trajectory.Narrative-Update • Dec 10
532834: Share Swap Acquisition Will Drive Long Term Returns
Analysts have modestly maintained their outlook on Camlin Fine Sciences, keeping the price target broadly unchanged near ₹240, as small tweaks to the discount rate and forward earnings assumptions continue to support a steady long term growth narrative. What's in the News Board meeting scheduled for November 10, 2025, to approve unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025, and to consider the reappointment of Mahabaleshwar Palekar as a non executive independent director (Key Developments).Narrative-Update • Nov 26
532834: Share Swap Acquisition And Margin Expansion Will Drive Future Returns
Analysts have lowered their price target for Camlin Fine Sciences from ₹270 to ₹240. They cite updated estimates that reflect improved profit margins and revenue growth, along with a reduced valuation multiple.Narrative-Update • Nov 11
532834: Acquisition Plan Will Drive Shareholder Value Despite Margin Pressure
Analysts have revised their price target for Camlin Fine Sciences downward from ₹295 to ₹270. They cited lower expected profit margins, even though revenue growth is projected to be stronger.Neues Narrative • Sep 04
Tariff Benefits And Safety Trends Will Boost US And Europe
Key Takeaways Plant restarts and easing exceptional expenses are set to improve margins, with structural growth driven by global demand for compliant, high-quality food additives. Favorable trade barriers and China+1 supply diversification position Camlin Fine Sciences for market share gains, margin expansion, and reduced dependence on legacy products.Aktionärsrenditen
| 532834 | IN Chemicals | IN Markt | |
|---|---|---|---|
| 7D | -3.4% | 2.1% | 1.9% |
| 1Y | -57.2% | -4.9% | -1.3% |
Rendite im Vergleich zur Industrie: 532834 unter dem Niveau der Branche Indian Chemicals , die im vergangenen Jahr eine Rendite von -4.9% erzielte.
Rendite vs. Markt: 532834 hinter dem Markt Indian zurück, der im vergangenen Jahr eine Rendite von -1.3 erzielte.
Preisvolatilität
| 532834 volatility | |
|---|---|
| 532834 Average Weekly Movement | 8.5% |
| Chemicals Industry Average Movement | 6.1% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in IN Market | 9.1% |
| 10% least volatile stocks in IN Market | 3.8% |
Stabiler Aktienkurs: Der Aktienkurs von 532834 war in den letzten 3 Monaten im Vergleich zum Indian -Markt volatil.
Volatilität im Zeitverlauf: 532834Die wöchentliche Volatilität (9%) war im vergangenen Jahr stabil, liegt aber immer noch höher als bei 75 % der Indian Aktien.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 1931 | 661 | Ashish Dandekar | www.camlinfs.com |
Camlin Fine Sciences Limited beschäftigt sich zusammen mit seinen Tochtergesellschaften mit der Forschung, Entwicklung, Herstellung und Vermarktung von Spezialchemikalien, Inhaltsstoffen und Zusatzstoffmischungen in Indien und international. Das Unternehmen bietet Haltbarkeitslösungen an, zu denen Antioxidantien wie Butylhydroxytoluol und Ascorbylpalmitat sowie Emulgatoren, Schimmelschutzmittel, antibakterielle Mittel, Toxinbinder, Pelletbinder, Desinfektionsmittel, Energizer, Konservierungsmittel, Verdickungsmittel und Wachstumsförderer sowie Antioxidantien auf pflanzlicher Basis wie gemischte Tocopherole, Grünteeextrakt und Rosmarinextrakt gehören, die zur Verbesserung der Haltbarkeit unter den Marken Xtendra und NaSure verwendet werden. Darüber hinaus bietet das Unternehmen Aromastoffe wie Vanillin und Ethylvanillin, Gesundheits- und Wellness-Produkte sowie Performance-Chemikalien wie Hydrochinon und Catechin an.
Camlin Fine Sciences Limited's Grundlagenzusammenfassung
| 532834 grundlegende Statistiken | |
|---|---|
| Marktanteil | ₹23.96b |
| Gewinn(TTM) | -₹274.47m |
| Umsatz(TTM) | ₹17.23b |
1.4x
Kurs-Umsatz-Verhältnis-87.3x
Kurs-Gewinn-Verhältnis Ist 532834 zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| 532834 Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | ₹17.23b |
| Kosten der Einnahmen | ₹9.22b |
| Bruttogewinn | ₹8.01b |
| Sonstige Ausgaben | ₹8.28b |
| Gewinn | -₹274.47m |
Zuletzt gemeldete Gewinne
Mar 31, 2026
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | -1.43 |
| Bruttomarge | 46.47% |
| Nettogewinnspanne | -1.59% |
| Schulden/Eigenkapital-Verhältnis | 66.8% |
Wie hat sich 532834 auf lange Sicht entwickelt?
Historische Performance und VergleicheUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/07/16 01:40 |
| Aktienkurs zum Tagesende | 2026/07/16 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2026/03/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Camlin Fine Sciences Limited wird von 9 Analysten beobachtet. 2 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Ankur Periwal | Axis Capital Limited |
| Abhishek Navalgund | Centrum Broking Limited |
| Satish Kumar | CGS International |